{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:35:18Z","timestamp":1793406918900,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40257-025-00995-z","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:55:04Z","timestamp":1763448904000},"page":"137-143","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Perioperative Systemic Therapy for High-Risk Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Kelly M.","family":"Kimball","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-1150","authenticated-orcid":false,"given":"Kathryn T.","family":"Shahwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"2","key":"995_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jaad.2021.03.109","volume":"85","author":"P Aggarwal","year":"2021","unstructured":"Aggarwal P, Knabel P, Fleischer AB. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol. 2021;85(2):388\u201395. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.109.","journal-title":"J Am Acad Dermatol"},{"key":"995_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1001\/jamadermatol.2015.4994","volume":"152","author":"AK Thompson","year":"2016","unstructured":"Thompson AK, Kelley BF, Prokop LJ, et al. Risk factors for cutaneous squamous cell carcinoma recurrence, metastasis, and disease-specific death: a systematic review and meta-analysis. JAMA Dermatol. 2016;152:419\u201328.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"995_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaad.2025.02.076","volume":"93","author":"A Jambusaria-Pahlajani","year":"2025","unstructured":"Jambusaria-Pahlajani A, Jeanselme V, Wang DM, Ran NA, Granger EE, Ca\u00f1ueto J, et al. RiSCC: a personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2025;93(1):73\u201381. https:\/\/doi.org\/10.1016\/j.jaad.2025.02.076.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"995_CR4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jaad.2024.11.082","volume":"92","author":"GA Zakhem","year":"2025","unstructured":"Zakhem GA, Qiblawi S, Shelton E, Xu YG. Prevalence of poor outcomes in cutaneous squamous cell carcinoma by AJCC and BWH tumor stages: a systematic review and meta-analysis. J Am Acad Dermatol. 2025;92(5):1064\u201371. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.082.","journal-title":"J Am Acad Dermatol"},{"key":"995_CR5","unstructured":"National Comprehensive Cancer Network. Squamous cell skin cancer (version 2.2025). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/squamous.pdf."},{"issue":"1","key":"995_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jaad.2022.03.044","volume":"87","author":"ES Ruiz","year":"2022","unstructured":"Ruiz ES, Kus KJB, Smile TD, Murad F, Zhou G, Ilori EO, et al. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: a dual-center retrospective study. J Am Acad Dermatol. 2022;87(1):87\u201394. https:\/\/doi.org\/10.1016\/j.jaad.2022.03.044.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"995_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1200\/JCO.1990.8.2.342","volume":"8","author":"TH Guthrie Jr","year":"1990","unstructured":"Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342\u20136. https:\/\/doi.org\/10.1200\/JCO.1990.8.2.342.","journal-title":"J Clin Oncol"},{"issue":"8","key":"995_CR8","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/1097-0142(19901015)66:8<1692::aid-cncr2820660807>3.0.co;2-y","volume":"66","author":"H Sadek","year":"1990","unstructured":"Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19901015)66:8%3c1692::aid-cncr2820660807%3e3.0.co;2-y.","journal-title":"Cancer"},{"issue":"1","key":"995_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00000421-199902000-00008","volume":"22","author":"S Denic","year":"1999","unstructured":"Denic S. Preoperative treatment of advanced skin carcinoma with cisplatin and bleomycin. Am J Clin Oncol. 1999;22(1):32\u20134. https:\/\/doi.org\/10.1097\/00000421-199902000-00008.","journal-title":"Am J Clin Oncol"},{"issue":"15","key":"995_CR10","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","volume":"25","author":"AM Brewster","year":"2007","unstructured":"Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, et al. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol. 2007;25(15):1974\u20138. https:\/\/doi.org\/10.1200\/JCO.2006.05.9873.","journal-title":"J Clin Oncol"},{"issue":"1","key":"995_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14978","volume":"33","author":"JP Pham","year":"2024","unstructured":"Pham JP, Rodrigues A, Goldinger SM, Sim HW, Liu J. Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: a systematic review and meta-analysis. Exp Dermatol. 2024;33(1):e14978. https:\/\/doi.org\/10.1111\/exd.14978.","journal-title":"Exp Dermatol"},{"issue":"2","key":"995_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/bjd.13741","volume":"173","author":"M Reigneau","year":"2015","unstructured":"Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015;173(2):527\u201334. https:\/\/doi.org\/10.1111\/bjd.13741.","journal-title":"Br J Dermatol"},{"issue":"01","key":"995_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000003","volume":"1","author":"D Jenni","year":"2016","unstructured":"Jenni D, Karpova MB, M\u00fchleisen B, et al. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open. 2016;1(01):e000003.","journal-title":"ESMO Open"},{"issue":"05","key":"995_CR14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","volume":"18","author":"CM Lewis","year":"2012","unstructured":"Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18(05):1435\u201346.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"995_CR15","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1002\/hed.26835","volume":"43","author":"PJ Kreinbrink","year":"2021","unstructured":"Kreinbrink PJ, Mierzwa ML, Huth B, Redmond KP, Wise-Draper TM, Casper K, et al. Adjuvant radiation and cetuximab improves local control in head and neck cutaneous squamous cell carcinoma: phase II study. Head Neck. 2021;43(11):3408\u201316. https:\/\/doi.org\/10.1002\/hed.26835.","journal-title":"Head Neck"},{"issue":"5 Suppl","key":"995_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jaad.2005.12.035","volume":"55","author":"Y Fujisawa","year":"2006","unstructured":"Fujisawa Y, Umebayashi Y, Ichikawa E, Kawachi Y, Otsuka F. Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: a report of two cases. J Am Acad Dermatol. 2006;55(5 Suppl):81\u20135. https:\/\/doi.org\/10.1016\/j.jaad.2005.12.035.","journal-title":"J Am Acad Dermatol"},{"key":"995_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/hed.24692","volume":"39","author":"M Amoils","year":"2017","unstructured":"Amoils M, Lee CS, Sunwoo J, et al. Node-positive cutaneous squamous cell carcinoma of the head and neck: survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head Neck. 2017;39:881\u20135.","journal-title":"Head Neck"},{"issue":"6","key":"995_CR18","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/hed.23684","volume":"37","author":"T Tanvetyanon","year":"2015","unstructured":"Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015;37(6):840\u20135. https:\/\/doi.org\/10.1002\/hed.23684.","journal-title":"Head Neck"},{"issue":"13","key":"995_CR19","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","volume":"36","author":"SV Porceddu","year":"2018","unstructured":"Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018;36(13):1275\u201383. https:\/\/doi.org\/10.1200\/JCO.2017.77.0941.","journal-title":"J Clin Oncol"},{"issue":"1","key":"995_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/ajd.13733","volume":"63","author":"N Aboul-Fettouh","year":"2022","unstructured":"Aboul-Fettouh N, Chen L, Ma J, Patel J, Silapunt S, Migden M. PD-1 inhibitors for cutaneous squamous cell carcinoma: a meta-analysis. Australas J Dermatol. 2022;63(1):36\u201342. https:\/\/doi.org\/10.1111\/ajd.13733.","journal-title":"Australas J Dermatol"},{"key":"995_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/bjophthalmol-2021-319417","volume":"107","author":"JA Goldfarb","year":"2023","unstructured":"Goldfarb JA, Ferrarotto R, Gross N, Goepfert R, Debnam JM, Gunn B, et al. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2023;107:320\u20133. https:\/\/doi.org\/10.1136\/bjophthalmol-2021-319417.","journal-title":"Br J Ophthalmol"},{"key":"995_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1001\/jamaoto.2024.0259","volume":"150","author":"EY Kim","year":"2024","unstructured":"Kim EY, Ruiz ES, DeSimone MS, Shalhout SZ, Hanna GJ, Miller DM, et al. Neoadjuvant-intent immunotherapy in advanced, resectable cutaneous squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2024;150:414\u201320. https:\/\/doi.org\/10.1001\/jamaoto.2024.0259.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"10","key":"995_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101727","volume":"17","author":"AM Lim","year":"2025","unstructured":"Lim AM, Baker B, Lion P, Angel CM, Simmons J, Jackson B, et al. Radiological, pathological, and surgical outcomes with neoadjuvant cemiplimab for stage II\u2013IV cutaneous squamous cell carcinoma in the Deep Sequencing in Cutaneous Squamous Cell Carcinomas (DISCERN) trial. Cancers (Basel). 2025;17(10):1727. https:\/\/doi.org\/10.3390\/cancers17101727.","journal-title":"Cancers (Basel)"},{"issue":"16","key":"995_CR24","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","volume":"27","author":"R Ferrarotto","year":"2021","unstructured":"Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, et al. Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2021;27(16):4557\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0585.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"995_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jamaoto.2023.1729","volume":"149","author":"R Ferrarotto","year":"2023","unstructured":"Ferrarotto R, Nagarajan P, Maronge JM, Johnson JM, Rosenthal DI, Myers JN, et al. Outcomes of treatment with neoadjuvant cemiplimab for patients with advanced, resectable cutaneous squamous cell carcinoma of the head and neck: secondary analysis of a phase 2 clinical trial. JAMA Otolaryngol Head Neck Surg. 2023;149(9):847\u20139.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"17","key":"995_CR26","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","volume":"387","author":"ND Gross","year":"2022","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. N Engl J Med. 2022;387(17):1557\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2209813.","journal-title":"N Engl J Med"},{"issue":"11","key":"995_CR27","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","volume":"24","author":"ND Gross","year":"2023","unstructured":"Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, et al. Neoadjuvant cemiplimab and surgery for stage II\u2013IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. Lancet Oncol. 2023;24(11):1196\u2013205. https:\/\/doi.org\/10.1016\/S1470-2045(23)00459-X.","journal-title":"Lancet Oncol"},{"key":"995_CR28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502449","author":"D Rischin","year":"2025","unstructured":"Rischin D, Porceddu S, Day F, Brungs DP, Christie H, Jackson JE, et al. Adjuvant cemiplimab or placebo in high-risk cutaneous squamous-cell carcinoma. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2502449.","journal-title":"N Engl J Med"},{"key":"995_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00387","author":"R Ladwa","year":"2025","unstructured":"Ladwa R, Lee JH, McGrath M, Cooper C, Liu H, Bowman J, et al. Response-adapted surgical and radiotherapy de-escalation in resectable cutaneous squamous cell cancer using pembrolizumab: the de-squamate study. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-25-00387.","journal-title":"J Clin Oncol"},{"key":"995_CR30","doi-asserted-by":"crossref","unstructured":"Koyfman SA, Lee JHJ, Mortier L, Bratland A, Luna-Romero NE, Chipman M, Dzienis M, Klochikhin M, Long J, Kirtbaya D, Monroe M, Gifoni MAC, Kaczmar JM, DeSimone J, Zambrano AR, Laurent CP, Shen J, Yuan J, Gumuscu B, Schenker M. Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT). J Clin Oncol. 2025:43(16 Supp).","DOI":"10.1200\/JCO.2025.43.16_suppl.6000"},{"issue":"1","key":"995_CR31","doi-asserted-by":"publisher","first-page":"e2400058","DOI":"10.1200\/OA-24-00058","volume":"1","author":"V Divi","year":"2024","unstructured":"Divi V, Aasi S, Khan SA, et al. Neoadjuvant atezolizumab in patients with surgically resectable advanced cutaneous squamous cell carcinoma. JCO Oncol Adv. 2024;1(1):e2400058.","journal-title":"JCO Oncol Adv."},{"key":"995_CR32","unstructured":"Clinicaltrials.gov."},{"key":"995_CR33","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.2147\/CCID.S381471","volume":"16","author":"L Mager","year":"2023","unstructured":"Mager L, Gardeen S, Carr DR, Shahwan KT. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma: appropriate patient selection and perspectives. Clin Cosmet Investig Dermatol. 2023;16:2135\u201342. https:\/\/doi.org\/10.2147\/CCID.S381471.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"995_CR34","doi-asserted-by":"publisher","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","volume":"20","author":"AJ Portuguese","year":"2022","unstructured":"Portuguese AJ, Tykodi SS, Blosser CD, Gooley TA, Thompson JA, Hall ET. Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review. J Natl Compr Canc Netw. 2022;20(4):406-416.e11. https:\/\/doi.org\/10.6004\/jnccn.2022.7009.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"995_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1200\/JCO.23.01498","volume":"42","author":"GJ Hanna","year":"2024","unstructured":"Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, et al. Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma. J Clin Oncol. 2024;42(9):1021\u201330. https:\/\/doi.org\/10.1200\/JCO.23.01498.","journal-title":"J Clin Oncol"},{"key":"995_CR36","unstructured":"Study of cemiplimab alone or in combination with fianlimab and\/or other experimental agents in adult participants with peri-operative stage III\/\u200bIV cutaneous squamous cell carcinoma (CSCC). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06384820?term=NCT06384820&rank=1. Accessed Sept 2025."},{"key":"995_CR37","unstructured":"Hamid O. Novel mechanisms in melanoma and beyond: emerging agents in NMSC. Presented at: 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies; February 8, 2025."},{"key":"995_CR38","unstructured":"A phase 1 study of pre-operative cemiplimab (REGN2810), administered intralesionally, for patients with cutaneous squamous cell carcinoma (CSCC) or basal cell carcinoma (BCC). Available from: https:\/\/clinicaltrials.gov\/study\/NCT03889912?term=NCT03889912&rank=1. Accessed Sept 2025."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00995-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:51:00Z","timestamp":1769849460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00995-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Drs. Kimball, Politi, and Shahwan declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Drs. Kimball, Politi, and Shahwan all conceptualized, drafted, and critically revised the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}